A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 70 adults with nerve pain related to diabetes randomised at one centre. 66 completed.
- Dose used in the study
- 600 mg a day of Levagen+
- Duration
- 8 weeks
- What was measured
- Pain severity and interference on the BPI-DPN questionnaire, and pain characteristics on the NPSI; sleep, mood, blood markers and safety
What the authors reported
Total pain, pain interference and NPSI scores were lower than placebo from week 2 onward (P ≤ 0.001), except for evoked pain (P = 0.09). Sleep scores improved (P ≤ 0.001), depression scores fell (P = 0.03) though anxiety and stress did not, and IL-6 and CRP were lower (P = 0.05) with no difference in fibrinogen. Adverse events were mild and short, and none led to withdrawal.
Limits of this study
One centre, 70 participants and 8 weeks. Most participants had type 2 diabetes, and blood sugar control varied. The authors called for larger studies. The authors declared no conflict of interest. The funding statement was not visible on the page checked.
Source
PubMed 36057884 · doi:10.1007/s10787-022-01033-8
Entry checked against the abstract on PubMed, and the article page at the publisher (Springer) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.